GlassScriptPhysician profile
Man C Duong
NPI 1679718399
$1,066.49
in general payments reported to CMS, 2019-2025
14 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.38 · 2022: $64.85 · 2023: $167 · 2024: $365 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $364.33 | 2022-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $219.54 | 2022-2025 | Wegovy, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.30 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $55.74 | 2024-2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $41.87 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $37.80 | 2025 | Rexulti |
| Shield Therapeutics INC | $36.23 | 2025 | |
| Lilly USA, LLC | $35.28 | 2025 | Jardiance, Mounjaro, Zepbound |
| Alnylam Pharmaceuticals INC. | $21.82 | 2023 | Amvuttra |
| Madrigal Pharmaceuticals | $21.69 | 2024 | Resmetirom |
| Merz North America, INC. | $20.68 | 2023 | Xeomin |
| Bayer Healthcare Pharmaceuticals INC. | $18.46 | 2025 | |
| Merck Sharp & Dohme LLC | $16.37 | 2024 | Zerbaxa, Dificid |
| Smith+Nephew, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Man Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.